Biohaven Stock Soars As FDA Accepts Vyglyxia Resubmission - This Plot Is Too Thick For Me
Biohaven jumps after FDA accepts Vyglyxia's NDA resubmission, but pipeline focus and approval risks cloud the outlook. Read the latest analysis on the BHVN stock here.